Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -534K | 0 | 0 | -6M | 0 |
| Operating Income | -53M | -74M | -159M | -206M | -156M |
| EBITDA | -52M | -63M | -147M | -217M | -153M |
| Net Income | -71M | -74M | -156M | -223M | -157M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$7.50
-0.79% today
1Y Change
-74.87%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Instil Bio, Inc. (TIL) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $7.50 and down 74.9% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +6.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +6.1%, free cash flow +44.3% with operating margin 0.0% and ROIC -39.5%. Stock Foundry combines TIL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TIL
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TIL Max Drawdown
-79.34%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TIL and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$156.8M
+29.7% YoY
Free Cash Flow
-$180.0M
+32.0% YoY
Revenue Growth
+0.0%
EPS Growth
+6.1%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -534K | 0 | 0 | -6M | 0 |
| Operating Income | -53M | -74M | -159M | -206M | -156M |
| EBITDA | -52M | -63M | -147M | -217M | -153M |
| Net Income | -71M | -74M | -156M | -223M | -157M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 7M | 9M | 9M | 44M | 38M |
| Total Assets | 204M | 264M | 326M | 482M | 610M |
| Total Liabilities | 90M | 94M | 100M | 119M | 55M |
| Shareholder Equity | 114M | 169M | 226M | 364M | 555M |
| Total Debt | 85M | 87M | 86M | 80M | 0 |
| Net Debt | 79M | 78M | 77M | 36M | -38M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
122M
+32.2% YoY
Capital Expenditures
58M
+31.6% YoY
Free Cash Flow
180M
+32.0% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-55.9%
Debt / Equity
0.75x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.